Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?
- 1 March 2016
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (5) , 426-436
Abstract
No abstract availableKeywords
Funding Information
- Medtronic
This publication has 26 references indexed in Scilit:
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary InterventionJACC, 2011
- Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial FibrillationJACC, 2011
- A Risk Score to Predict Bleeding in Patients With Acute Coronary SyndromesJACC, 2010
- Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantationAmerican Heart Journal, 2009
- Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial InfarctionCirculation, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- A Cause for ConcernCirculation, 2007
- Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery DiseaseJACC, 2006
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003